为您找到相关结果约17个

你是不是要搜索 期刊KALYDECO 点击跳转

Sites associated with Kalydeco binding on human Cystic Fibrosis Transmembrane Conductance Regulator revealed

WEIGHT INCREASE IN CF PATIENTS ON KALYDECO IS DUE TO DECREASE IN RESTING ENERGY EXPENDITURE AND ASSOCIATED

Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development

Tezacaftor/Ivacaftor (Symdeko) for Cystic Fibrosis

CFTR potentiators: from bench to bedside

One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies

Innovations in Thermal Processing: Hot-Melt Extrusion and KinetiSol (R) Dispersing

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Frequency of CFTR variants in southern Brazil and indication for modulators therapy in patients with cystic fibrosis

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults

Determination of ivacaftor by liquid chromatography techniques in pharmaceutical formulation with interlaboratory comparison and characterization of five novel degradation products by high-performance liquid chromatography ion trap time-of-flight mass spectrometry

The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements

CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy

Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation

Functional Defect of Variants in the Adenosine Triphosphate-Binding Sites of ABCB4 and Their Rescue by the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Ivacaftor ( VX-770)

为您找到相关结果约17个

共17条页码: 1/2页15条/页